← ANALYST RATINGS · TIPRANKS
Qiagen (QGEN): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy5 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $47.97, the highest $55.00, the lowest $40.00. The average is +4.0% from the last price of $46.13.
Analyst ratings 19
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $50.00 → $55.00+10.0% | Buy | +19.2% | Reiterated | 14.10.26on TipRanks 06:10 | +1.3%next day +1.1% | ↗ |
| Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% | UBS | $49.00 → $50.00+2.0% | Buy | +8.4% | Reiterated | 09.10.26on TipRanks Oct 11 09:55 | +1.3%next day −0.1% · 5 days +3.6% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $40.00 → $55.00+37.5% | Buy | +19.2% | Upgrade | 06.10.26on TipRanks 06:10 | −0.9%next day −1.6% · 5 days −0.3% | ↗ |
| Jan Koch★★★★★★★★★★#12061 · hits 31% · avg −10.4% | Deutsche Bank | $47.00 | Buy | +1.9% | Reiterated | 24.09.26on TipRanks Sep 25 01:50 | +2.0%next day −1.4% · 5 days −5.2% | ↗ |
| Aisyah Noor★★★★★★★★★★#5618 · hits 47% · avg +3.3% | Morgan Stanley | $44.95 → $47.20+5.0% | Buy | +2.3% | Reiterated | 11.09.26on TipRanks Sep 14 02:10 | 0.0%next day −1.0% · 5 days +2.0% | ↗ |
| Harry Gillis★★★★★★★★★★#1398 · hits 69% · avg +21.0% | Berenberg Bank | $45.50 | Hold | −1.4% | Reiterated | 10.09.26on TipRanks Sep 11 04:35 | −0.3%next day 0.0% · 5 days +4.7% | ↗ |
| Unknown Analyst | UBS | $52.00 → $47.00−9.6% | Hold | +1.9% | Initiated | 08.09.26on TipRanks Sep 11 04:35 | −2.0%next day +0.7% · 5 days +1.4% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Assigned | 24.08.26on TipRanks 15:15 | −4.9%next day +4.2% · 5 days +3.1% | ↗ |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $47.00 → $49.00+4.3% | Buy | +6.2% | Upgrade | 20.08.26on TipRanks 00:05 | — | |
| Unknown Analyst | DZ BANK AG | — | Buy | — | Reiterated | 12.08.26on TipRanks 22:05 | −0.2%next day −0.5% · 5 days +5.8% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $40.00 | Hold | −13.3% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | −2.4%next day +0.6% · 5 days −0.4% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $50.00 | Buy | +8.4% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | +3.7%next day −2.4% · 5 days −2.8% | ↗ |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $48.00 → $49.00+2.1% | Buy | +6.2% | Reiterated | 10.08.26on TipRanks 10:06 | — | |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $48.00 → $49.00+2.1% | Buy | +6.2% | Reiterated | 10.08.26on TipRanks 10:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $45.00 → $46.00+2.2% | Hold | −0.3% | Reiterated | 10.08.26on TipRanks 10:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $48.00 → $49.00+2.1% | Buy | +6.2% | Reiterated | 10.08.26on TipRanks 10:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $47.00 | Buy | +1.9% | Reiterated | 10.08.26on TipRanks 10:06 | — | |
| Name not given | — | $38.00 → $45.00+18.4% | Hold | −2.4% | Reiterated | 10.08.26on TipRanks 06:45 | +3.7%next day −2.4% · 5 days −2.8% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | — | Buy | — | Reiterated | 06.08.26on TipRanks 08:50 | −0.4%next day +0.8% · 5 days +2.4% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $40.00 → $44.00+10.0% | Hold | −4.6% | Reiterated | 15.07.26on TipRanks 08:50 | −1.2%next day +1.2% · 5 days −0.6% | ↗ |
| Unknown Analyst | Kepler Capital | $38.60 | Hold | −16.3% | Initiated | 25.06.26on TipRanks Jul 1 21:01 | +0.4%next day +1.9% · 5 days +1.6% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $49.00 | Buy | +6.2% | Reiterated | 13.05.26on TipRanks May 14 04:35 | −3.5%next day +1.0% · 5 days +7.5% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $53.00 → $43.00−18.9% | Buy | −6.8% | Upgrade | 29.04.26on TipRanks 05:10 | −1.2%next day +1.9% · 5 days −0.7% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $52.00 | Hold | +12.7% | Reiterated | 09.02.26on TipRanks 06:55 | −0.8%next day +0.9% · 5 days −2.4% | ↗ |
| Jack Meehan★★★★★★★★★★#787 · hits 68% · avg +14.4% | Nephron | $59.00 | Hold | +27.9% | Downgrade | 21.01.26on TipRanks 07:50 | −0.8%next day −3.1% · 5 days −4.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Qiagen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $46.74 at a price of $45.79 (+2.1%); now: $47.97 at $46.13 (+4.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 9 | 12 | 9 | 12 | 10 | 11 |
| Hold | 10 | 13 | 11 | 15 | 14 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.62 (from $0.61 to $0.64). Last quarter: $0.62.
Sales
Next quarter’s sales estimate — $536M (from $531M to $538M). Last quarter: $535M.
Best top-analyst consensus in the sector · Healthcare
About Qiagen
- CEO: Jon Pratt
- Employees: 5,500
- Hulsterweg 82, Venlo, LI, 5912 PL, NL
- www.qiagen.com
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Data from the stock’s TipRanks forecast page, read 72 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗